長遠鋰科(688779.SH):子公司擬投建年產6萬噸磷酸鐵鋰正極材料項目
格隆匯12月30日丨長遠鋰科(688779.SH)公佈,為進一步鞏固並提升公司市場地位,增強公司市場競爭力,實現企業效益最大化和佈局多元化,在現有三元正極材料、鈷酸鋰正極材料業務的基礎上拓展磷酸鐵鋰正極材料業務,公司全資子公司湖南長遠鋰科新能源有限公司(“長遠新能源”)擬投資建設年產6萬噸磷酸鐵鋰正極材料項目,該項目總投資約為20.88億元。
鋰電池正極材料存在多種技術路線,目前市場上形成規模化應用的鋰電池正極材料包括鈷酸鋰、錳酸鋰、磷酸鐵鋰、三元正極材料。但鋰電池技術的發展日新月異,鋰電池正極材料也在不斷的演進和進行技術迭代,未來公司產品存在技術被趕超、產品被替代的風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.